Bio-Rad is extending ddPCR systems into oncology, biopharma quality control and cell & gene therapy release testing. The company faces near-term headwinds with anticipated challenges in the biopharma market and among small biotech companies, with ongoing uncertainty in the Chinese market expected to persist into 2026, but maintains strategic focus on acquisitions and margin improvement.
Cyborg Score Rationale
Bio-Rad demonstrates solid operational fundamentals with $1.541 billion in cash and short-term investments and Clinical Diagnostics showing clear strength with 8.4% reported growth. However, Life Science segment challenges and modest 2026 guidance of 0.5%–1.5% currency-neutral revenue growth limit upside momentum.
Top Insights
ddPCR portfolio delivered mid-single-digit growth in Q4 2025 with strong QX700 instrument sales momentum; platform positioned as core long-term growth pillar
Process chromatography delivered more than 20% growth in 2025 from select therapeutics and vaccines, but business is inherently lumpy and concentrated
Market capitalization approximately $4.45 billion based on Class A Common Stock held by non-affiliates
Repurchased 1.9 million shares since early 2024, reducing share count by approximately 6.6%
Named Competitors
Thermo Fisher — Life sciences and diagnostics equipment provider
Danaher — Diversified conglomerate with diagnostics and life sciences platforms
Abbott Diagnostics — Clinical diagnostics and molecular testing solutions
Roche Diagnostics — In vitro diagnostics and clinical laboratory systems
Recent Developments
(February 2026) Annual Form 10-K report filed with net sales of $2,583.2 million, up 0.7% year-over-year
(February 2026) 2026 guidance issued for 0.5%–1.5% currency-neutral revenue growth with Q1 declining low single digits before improving
(Q4 2025) Q4 2025 net sales of $693 million, up 3.9% reported and 1.7% currency-neutral
Open the full interactive Bio-Rad Laboratories, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.